# Modalis Therapeutics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/modalis-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.modalistx.com/jp
- Total disclosed funding: $36M
- Latest round: Series B (May 24, 2019)
- Investors on record: 10

## About

Modalis Therapeutics Corporation is a biotechnology company focused on gene therapy and genome editing technologies designed to treat genetic disorders with innovative therapeutic solutions.Founded in 2016 by Haru Morita, Modalis Therapeutics Corporation operates from Tokyo, Japan. The company specializes in developing gene therapies and has executed six deals to date, with its most recent deal occurring on June 26, 2020. Modalis raised JPY 3240 million in an IPO, selling 2.7 million shares at JPY 1200 per share on the Tokyo Stock Exchange Mother Sections. Haru Morita, the CEO and founder, has a history of involvement in biotechnology ventures.Modalis Therapeutics Corporation specializes in gene therapy and genome editing technologies aimed at treating genetic disorders. The company's core product offerings include MDL-207, a treatment for Dravet Syndrome, and MDL-101, which targets muscle dystrophies through epigenome editing. These therapies utilize advanced technologies such as CRISPR for precise gene modification and epigenome editing to control gene expression without altering the DNA sequence, providing effective solutions for conditions that currently lack comprehensive treatments. The products are primarily aimed at healthcare providers and research institutions in the United States and Europe.In 2022, Modalis Therapeutics recorded a revenue of JPY 310,136,000, while the EBITDA for the same year was JPY -14,852,214,800.Looking ahead, Modalis Therapeutics plans to expand its product lineup and enter new markets. The company will leverage the JPY 3240 million raised in its recent IPO to enhance its research capabilities and expedite the development of upcoming gene therapies. This includes targeted efforts to launch additional products focused on genetic disorders by 2024 and expanding its reach into new geographic regions in Asia and Europe, aligning with its strategic vision for growth.

## Funding rounds

- Series B, May 24, 2019, $8.2M — Pegasus Tech Ventures, Shinsei Capital Partners
- Series B, Apr 10, 2019, $14M — SMBC Venture Capital, Mizuho Capital, SBI Investment, Fast Track Initiative, UTokyo Innovation Platform, CareNet Group
- Series A, Dec 20, 2017, $5.3M — SMBC Venture Capital, Mizuho Capital, SBI Investment, Fujifilm Holdings Corporation, Fast Track Initiative
- Series A, Oct 6, 2017, $8M — PF Capital

## Investors

- PF Capital (https://capitalatlas.ai/funds/pf-capital) — Series A
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series B
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A, Series B
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A, Series B
- Fujifilm Holdings Corporation — Series A
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series A, Series B
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series B
- CareNet Group — Series B
- Pegasus Tech Ventures (https://capitalatlas.ai/funds/pegasus-tech-ventures) — Series B
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series B